Garuda - Garba Rujukan Digital

p-Index From 2020 - 2025

0.61

P-Index

This Author published in this journals

All Journal The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy

Rino Alvani Gani

Division of Hepatobiliary, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General National Hospital, Jakarta

Author-ID : 5436203

Medicine & Pharmacology

Published : 5 Documents Claim Missing Document

Claim Missing Document

Articles

Procalcitonin Level Differences in Patients with Liver Cirrhosis Without Bacterial Infection Oska Mesanti; Rino Alvani Gani; Marcellus Simadibrata; Suhendro Suhendro
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 18, No 1 (2017): VOLUME 18, NUMBER 1, April 2017
Publisher : The Indonesian Society for Digestive Endoscopy

Background: Procalcitonin level can increase in patients with liver cirrhosis without bacterial infection. The aim of this study is to identify the role of procalcitonin in patients with liver cirrhosis without bacterial infection.Methods: Cross-sectional study was performed to patients with liver cirrhosis without bacterial infection. In patients, we performed procalcitonin level examination and bacterial infection identification. Further, we analysed them to know the procalcitonin level difference in patients with compensated and decompensated liver cirrhosis without bacterial infection.Results: We obtained 39 patients with liver cirrhosis without bacterial infection, male 61.5% with compensated condition found in 17 patients and decompensated in 22 patients. We found significant difference in the average of procalcitonin level in decompensated patients (0.738ng/mL ± 1.185) compared to compensated (0.065ng/mL ± 0.022).Conclusion: Procalcitonin level increased in patients with liver cirrhosis without bacterial infection. The level in decompensated patients were higher compared to compensated patients.

Impact of Endoscopic Ultrasound (EUS) Procedure in Pancreatico-biliary Disorders in Indonesia Cosmas Rinaldi A Lesmana; Rino Alvani Gani; Irsan Hasan; Andri Sanityoso Sulaeman; Laurentius A Lesmana
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 18, No 1 (2017): VOLUME 18, NUMBER 1, April 2017
Publisher : The Indonesian Society for Digestive Endoscopy

Pancreato-biliary disorders are the challenging disorders in gastroenterology practice. It is well-known that endoscopic retrograde cholangiopancreatography (ERCP) is a common procedure in managing pancreato-biliary disorders. However, imaging modalities such as abdominal CT scan and MRI has been successfully reduced the unnecessary ERCP to avoid several potential complications. Recently, endoscopic ultrasound (EUS) procedure has become an important tool due to the limitation of imaging modalities in pancreato-biliary disorders. Its ability which is not only for diagnostic, but also for therapeutic purpose has given a new insight for most gastroenterologists in their daily practice. However, the investment, cost, and the proper training curriculum are still debatable in most developing countries, especially in Indonesia.

Primary Tupaia Javanica Hepatocyte Culture as an In Vitro Model for Human Hepatitis B Virus Infection Kemal Fariz Kalista; Maryati Surya; Silmi Mariya; Diah Iskandriati; Irsan Hasan; Rino Alvani Gani
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 22, No 3 (2021): VOLUME 22, NUMBER 3, December 2021
Publisher : The Indonesian Society for Digestive Endoscopy

Background: Hepatitis B virus (HBV) infection is still one of the biggest health problems in the world, which could lead to chronic hepatitis, cirrhosis and hepatocellular carcinoma. Treatment for HBV infection has not yet achieved a functional cure. More studies are needed to investigate human HBV (HuHBV), but the scarcity of animal models for HuHBV infection became a barrier. Recently, many studies have shown that Tupaia are suitable for the study of HuHBV. The purpose of this study was to develop a primary tupaia hepatocyte (PTH) culture from T. javanica, a species of Tupaia found in Indonesia, and to prove that HuHBV can replicate in the PTH.Method: In vitro experimental study using PTH isolated from five wild adult T. javanica in Primate Research Center, IPB University. HuHBV was taken from humans with HBsAg and HBV-DNA (+). PTH cells then were infected with HuHBV after reaching 80% confluence. Observation on PTH cells was done everyday for 20 days. Qualitative and quantitative HBsAg were measured using a CMIA while HBV-DNA and cccDNA were measured by RT-PCR.Results: A cytopathic effect was seen on day post infection (DPI)-16. HBsAg and HBV-DNA were detected from DPI-2 until DPI-18, with HBV-DNA level peaked on DPI-12. cccDNA concentration was fluctuating from DPI-2 until DPI-20 with highest level on DPI-16.Conclusion: HuHBV could infect and replicate in PTH from T. javanica can be infected with HuHBV and HuHBV can replicate in the PTH from T. javanica.

One-year Survival Rate of Pancreatic Cancer and the Mortality Affecting Factors Alexander Michael Joseph Saudale; Marcellus Simadibrata; Rino Alvani Gani; Cleopas Martin Rumende
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 21, No 2 (2020): VOLUME 21, NUMBER 2, August 2020
Publisher : The Indonesian Society for Digestive Endoscopy

Background: Pancreatic cancer is the fourth leading cause of death associated with malignancy in the United States, and is thought to be the second leading cause of death in 2030 in the United Kingdom. In Asia, pancreatic cancer is the most fatal cancer with the lowest survival of all malignancies, 25-30% survival five years after surgery. Indonesia has no data on the survival of pancreatic cancer and the factors that affect it. The aim of this study is knowing the 1-year survival of pancreatic cancer and its influencing factors in Cipto Mangunkusumo Hospital, Jakarta.Method: A retrospective cohort study was performed using data from the medical records of pancreatic cancer patients dr. Cipto Mangunkusumo Hospital between January 2012 - December 2016. Factors age, sex, metastasis, stage, comorbid and treatment were analyzed bivariate and multivariate using Cox Proportional Hazards Regression to obtain Hazard Ratio (HR) for each prognostic factor. The cumulative survival of 1 year after diagnosis is expressed by the Kaplan-Meier curve.Results: Of 83 subjects the proportion of males was 62.7%, age ≥ 50 years 68.7%, with age range 33-79 years, and 55 years on average. In bivariate analysis, there was a statistically significant relationship of survival with comorbid variables (HR = 2,116, 95% 953 1,335-3,513, p 0,002), metastasis (HR = 3,802, 95% CI: 1,995-7,249, p 0.001), palliative treatment (HR = 2,108 , 95% CI: 1,077-4,125, p = 0,029) and group without treatment (HR = 2,924, 95% CI: 1,496-5,716, p = 0,002). Multivariate analysis showed that metastasis provided the greatest risk of death with HR = 4.306 (95% CI: 2.125-8.724, p 0.001). Palliative group HR was 2.510 (95% CI: 1,245-5,061 p = 0.010) while the group without treatment gave HR 2,535 (95% CI: 1,277-5,032 p = 0,008). The 1-year survival rate is 14%, with a median survival of 6 months.Conclusion: The overall survival of one year of pancreatic cancer patients was 14%, with a median survival of 6 months. The presence of metastasis and not the curative therapy of Whipple surgery in patients with pancreatic cancer in dr. Cipto Mangunkusumo Hospital is the main factor that negatively affect the survival of 1 year

COVID-19 Related to Liver Impairment and Its Impact on Chronic Liver Disease Andri Sanityoso Sulaiman; Juferdy Kurniawan; Chyntia Olivia Maurine Jasirwan; Saut HH Nababan; Kemal F Calista; Cosmas Rinaldi A Lesmana; Irsan Hasan; Rino Alvani Gani; Baiq Kirana DN Mandasari
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 21, No 3 (2020): VOLUME 21, NUMBER 3, December 2020
Publisher : The Indonesian Society for Digestive Endoscopy

By late December 2019, a novel beta-coronavirus, named as COVID-19 (2019-nCoV), was discovered in Wuhan, Hubei Province, China which epidemiologically linked to a Huanan seafood market in Wuhan. Coronavirus Disease 2019 or COVID-19 cases are growing rapidly from Wuhan to many countries, finding the health care system unprepared to face this threat. No effective drugs are clinically approved to manage the disease and strategies to protect the most vulnerable from developing severe illness and infection is still unclear. Information on how COVID-19 virus infection may affects many organs, especially the liver and the relevance of pre-existing liver disease in patients as a risk factor for the infection or disease severity are still scarce and inconclusive. Besides, the recommendation and consideration in liver transplant patients, hepatocellular carcinoma, or patient on immunosuppressive therapy still need further analysis Therefore, the information on the mechanism and treatment of COVID-19 related liver injury in patients with or without pre-existing liver disease should be considered.

Co-Authors Alexander Michael Joseph Saudale Andri Sanityoso Sulaeman Andri Sanityoso Sulaiman Baiq Kirana DN Mandasari C Rinaldi A Lesmana Chyntia Olivia Maurine Jasirwan, Chyntia Olivia Maurine Cleopas Martin Rumende Diah Iskandriati Irsan Hasan Juferdy Kurniawan Kemal F Calista Kemal Fariz Kalista Laurentius A Lesmana Marcellus Simadibrata Marcellus Simadibrata Maryati Surya Oska Mesanti Saut HH Nababan Silmi Mariya Suhendro Suhendro

Title

Found 5 Documents
Search

Abstract

Abstract

Abstract

Abstract

Abstract

Title Search

Found 5 Documents Search

Abstract

Abstract

Abstract

Abstract

Abstract

Title

Found 5 Documents
Search